Switch theme
Sign up to access all valuation multiples
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
2004
9
LTM Revenue $13.1M
Last FY EBITDA -$53.7M
$161M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Aldeyra Therapeutics has a last 12-month revenue (LTM) of $13.1M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Aldeyra Therapeutics achieved revenue of n/a and an EBITDA of -$53.7M.
Aldeyra Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Aldeyra Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $13.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $12.7M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 97% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$53.7M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$47.9M | XXX | -$60.1M | XXX | XXX | XXX |
| EBIT Margin | -367% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$44.5M | XXX | -$55.9M | XXX | XXX | XXX |
| Net Margin | -341% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Aldeyra Therapeutics's stock price is $4.
Aldeyra Therapeutics has current market cap of $235M, and EV of $161M.
See Aldeyra Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $161M | $235M | XXX | XXX | XXX | XXX | $-0.75 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Aldeyra Therapeutics has market cap of $235M and EV of $161M.
Aldeyra Therapeutics's trades at n/a EV/Revenue multiple, and -3.0x EV/EBITDA.
Equity research analysts estimate Aldeyra Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aldeyra Therapeutics has a P/E ratio of -5.3x.
See valuation multiples for Aldeyra Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $235M | XXX | $235M | XXX | XXX | XXX |
| EV (current) | $161M | XXX | $161M | XXX | XXX | XXX |
| EV/Revenue | 12.3x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -3.0x | XXX | XXX | XXX |
| EV/EBIT | -3.4x | XXX | -2.7x | XXX | XXX | XXX |
| EV/Gross Profit | 12.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.3x | XXX | -4.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAldeyra Therapeutics's last 12 month revenue growth is 291%
Aldeyra Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $6.7M for the same period.
Aldeyra Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aldeyra Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Aldeyra Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 291% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $6.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aldeyra Therapeutics acquired XXX companies to date.
Last acquisition by Aldeyra Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Aldeyra Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Aldeyra Therapeutics founded? | Aldeyra Therapeutics was founded in 2004. |
| Where is Aldeyra Therapeutics headquartered? | Aldeyra Therapeutics is headquartered in United States of America. |
| How many employees does Aldeyra Therapeutics have? | As of today, Aldeyra Therapeutics has 9 employees. |
| Who is the CEO of Aldeyra Therapeutics? | Aldeyra Therapeutics's CEO is Dr. Todd C. Brady, M.D.,PhD. |
| Is Aldeyra Therapeutics publicy listed? | Yes, Aldeyra Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Aldeyra Therapeutics? | Aldeyra Therapeutics trades under ALDX ticker. |
| When did Aldeyra Therapeutics go public? | Aldeyra Therapeutics went public in 2014. |
| Who are competitors of Aldeyra Therapeutics? | Similar companies to Aldeyra Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Aldeyra Therapeutics? | Aldeyra Therapeutics's current market cap is $235M |
| What is the current revenue of Aldeyra Therapeutics? | Aldeyra Therapeutics's last 12 months revenue is $13.1M. |
| What is the current revenue growth of Aldeyra Therapeutics? | Aldeyra Therapeutics revenue growth (NTM/LTM) is 291%. |
| What is the current EV/Revenue multiple of Aldeyra Therapeutics? | Current revenue multiple of Aldeyra Therapeutics is 12.3x. |
| Is Aldeyra Therapeutics profitable? | Yes, Aldeyra Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
